Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A
6(100.0%)
6Total
N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04689009Not ApplicableCompleted

Leg Ulcers Standards of Care Enhancement

Role: lead

NCT05130814Not ApplicableCompleted

EmoLED Medical Device Treatment of Second and Third Stage Pressure Ulcers

Role: lead

NCT04831606Not ApplicableTerminated

Blue Light Photobiomodulation Therapy on Neuroischemic Patients

Role: lead

NCT05181644Not ApplicableTerminated

Effectiveness of the EmoLED Medical Device in the Healing of Digital Ulcers in Patients With Scleroderma.

Role: lead

NCT04951934Not ApplicableWithdrawn

Prospective Randomized International Study on the Reactivation of Burn Injuries

Role: lead

NCT04018924Not ApplicableCompleted

Blu Light for Ulcers Reduction

Role: lead

All 6 trials loaded